NEOGENOMICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NeoGenomics, Inc. - NEO

Münzen, die repräsentativ für Ethereum stehen. © Lightboxx/iStock / Getty Images Plus/Getty Images

PR Newswire

NEW ORLEANS, Jan. 27, 2023

NEW ORLEANS, Jan. 27, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 6, 2023 to file lead plaintiff applications in a securities class action lawsuit against NeoGenomics, Inc. (NasdaqCM: NEO), if they purchased the Company's securities between February 27, 2020 and April 26, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

Get Help

NeoGenomics investors should visit us at https://claimsfiler.com/cases/nasdaq-neo/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

NeoGenomics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On March 28, 2022, the Company disclosed that its CEO was stepping down effective immediately, that it expected 1Q2022 revenue and EBITDA below the low end of its prior guidance, and that it had withdrawn its 2022 annual financial guidance. On this news, shares of NeoGenomics fell $5.30 per share, or 29.8%. Then, on April 27, 2022, the Company disclosed its 1Q2022 financial results confirming revenue and EBITDA below its prior guidance, among other things, that the market "was moving towards larger, more comprehensive panels" and that the Company was "seeing bigger and bigger panels coming from…emerging companies . . . where we have not kept up." On this news, shares of NeoGenomics fell $0.41 per share, or 3.8%.

The case is Goldenberg v. NeoGenomics, Inc., No. 22-cv-10314.

ARIVA.DE Börsen-Geflüster

Kurse

Neogenomics

14,15 $

-2,01%

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

View original content:https://www.prnewswire.com/news-releases/neogenomics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-neogenomics-inc---neo-301732708.html

SOURCE ClaimsFiler

Mehr Nachrichten zur Neogenomics Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.